Search research articles
Contact Us
Filters
Showing results (1-10 of 18) with videos related to
Page
of 2
Sort By:
Optics Letters
|
January 16, 2025
High-order super-resolution optical fluctuation imaging with ultrasmall polymer dots
Mingyue Gong, Zhuli Wu, Jie Liu, et al.
Neuroscience Letters
|
February 8, 2022
Pulsed infrared stimulation evoked electrical potential in mouse vestibular system
Weitao Jiang, Zihan Wang, Shijie Xiao, et al.
ACS Sensors
|
February 13, 2026
Visible-Light Driven Implantable Nanophotonic Biosensor for Continuous Glucose Monitoring via Metalloporphyrin Q-Band Modulation and Enzymatic Cascade Stabilization
Xinyu Wang, Zhuli Wu, Shuangyu Bai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 13, 2026
A phase 2 study of the MEK1/2 inhibitor luvometinib in patients with extracranial arteriovenous malformations
Chen Hua, Zhuli Wu, Xingli Wang, et al.
British Journal of Clinical Pharmacology
|
November 5, 2023
Model-informed dose selection for an investigational human epidermal growth factor receptor 2 antibody-drug conjugate FS-1502 in patients with human epidermal growth factor receptor 2-expressing advanced malignant solid tumours
Yi Sun, Chao Li, Xingli Wang, et al.
Nano Letters
|
February 13, 2026
Noninvasive Salivary Ketone Monitoring: A Ratiometric Pdot Biosensor toward Personalized Ketogenic Management
Mingyue Gong, Zhuli Wu, Shiyu Wang, et al.
Toxics
|
July 25, 2025
MWB_Analyzer: An Automated Embedded System for Real-Time Quantitative Analysis of Morphine Withdrawal Behaviors in Rodents
Moran Zhang, Qianqian Li, Shunhang Li, et al.
Frontiers in Pharmacology
|
February 9, 2023
Population pharmacokinetics of FCN-159, a MEK1/2 inhibitor, in adult patients with advanced melanoma and neurofibromatosis type 1 (NF1) and model informed dosing recommendations for NF1 pediatrics
Yan Tan, Ailing Cui, Lixuan Qian, et al.
Investigational New Drugs
|
June 10, 2021
Phase 1a study of the CDK4/6 inhibitor, FCN-437c, in Chinese patients with HR + /HER2- advanced breast cancer
Jian Zhang, Xiaojia Wang, Xian Wang, et al.
Advances in Therapy
|
January 10, 2023
Effect of Food (Low and High Fat) on Pharmacokinetics of FCN-159, a Selective MEK Inhibitor, in Healthy Chinese Males
Jiangfan Li, Yan Tan, Kexin Li, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 18) with videos related to
Sort By:
Page
of 2
Optics Letters
|
January 16, 2025
High-order super-resolution optical fluctuation imaging with ultrasmall polymer dots
Mingyue Gong, Zhuli Wu, Jie Liu, et al.
Neuroscience Letters
|
February 8, 2022
Pulsed infrared stimulation evoked electrical potential in mouse vestibular system
Weitao Jiang, Zihan Wang, Shijie Xiao, et al.
ACS Sensors
|
February 13, 2026
Visible-Light Driven Implantable Nanophotonic Biosensor for Continuous Glucose Monitoring via Metalloporphyrin Q-Band Modulation and Enzymatic Cascade Stabilization
Xinyu Wang, Zhuli Wu, Shuangyu Bai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 13, 2026
A phase 2 study of the MEK1/2 inhibitor luvometinib in patients with extracranial arteriovenous malformations
Chen Hua, Zhuli Wu, Xingli Wang, et al.
British Journal of Clinical Pharmacology
|
November 5, 2023
Model-informed dose selection for an investigational human epidermal growth factor receptor 2 antibody-drug conjugate FS-1502 in patients with human epidermal growth factor receptor 2-expressing advanced malignant solid tumours
Yi Sun, Chao Li, Xingli Wang, et al.
Nano Letters
|
February 13, 2026
Noninvasive Salivary Ketone Monitoring: A Ratiometric Pdot Biosensor toward Personalized Ketogenic Management
Mingyue Gong, Zhuli Wu, Shiyu Wang, et al.
Toxics
|
July 25, 2025
MWB_Analyzer: An Automated Embedded System for Real-Time Quantitative Analysis of Morphine Withdrawal Behaviors in Rodents
Moran Zhang, Qianqian Li, Shunhang Li, et al.
Frontiers in Pharmacology
|
February 9, 2023
Population pharmacokinetics of FCN-159, a MEK1/2 inhibitor, in adult patients with advanced melanoma and neurofibromatosis type 1 (NF1) and model informed dosing recommendations for NF1 pediatrics
Yan Tan, Ailing Cui, Lixuan Qian, et al.
Investigational New Drugs
|
June 10, 2021
Phase 1a study of the CDK4/6 inhibitor, FCN-437c, in Chinese patients with HR + /HER2- advanced breast cancer
Jian Zhang, Xiaojia Wang, Xian Wang, et al.
Advances in Therapy
|
January 10, 2023
Effect of Food (Low and High Fat) on Pharmacokinetics of FCN-159, a Selective MEK Inhibitor, in Healthy Chinese Males
Jiangfan Li, Yan Tan, Kexin Li, et al.
Page
of 2